This trial is active, not recruiting.

Condition lymphoma
Treatments fludeoxyglucose f18, computed tomography, positron emission tomography
Sponsor Abramson Cancer Center of the University of Pennsylvania
Start date May 2009
End date July 2013
Trial size 10 participants
Trial identifier NCT01004718, NCI-2009-01348, UPCC 21408


RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell lymphoma.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose diagnostic
Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
fludeoxyglucose f18 18FDG, FDG, Fluorine-18, 2 Fluoro-2-deoxy-D-Glucose, Fludeoxyglucose F18
Undergo FDG PET/CT scans
computed tomography tomography, computed
Undergo FDG PET/CT scans
positron emission tomography FDG-PET, PET, PET scan, tomography, emission computed
Undergo FDG PET/CT scans

Primary Outcomes

Amount of lesional FDG uptake (assessed by qualitative assessment, standardized uptake value (SUV), and lesion to background uptake ratios)
time frame: At 60 and 180 minutes after FDG administration
Rate of change of lesional FDG uptake (measured by change in SUV)
time frame:
Characteristics of lesional SUV frequency histograms (e.g., mean, standard deviation, full-width-half-maximum (FWHM), etc.) and/or lesional SUV heterogeneity maps, along with changes in these characteristics
time frame:

Secondary Outcomes

Effect of lesion size (e.g., lesions = 3 cm) on primary outcome variables.
time frame:
Effect of lesion location on primary outcome variables (e.g., nodal vs extranodal)
time frame:
Effect of imaging delay time of PET image acquisition upon number of lymphomatous lesions detected
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with measurable disease by any imaging technique or physical examination. Exclusion Criteria: - Pregnant or nursing, - Uncontrolled diabetes mellitus, - Active infection, - Inability to give informed consent or to comply with all study procedures, - Subjects may be excluded at the discretion of the principal investigator or study team members.

Additional Information

Official title A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging
Description OBJECTIVES: I. Assess the feasibility of detection and quantification of differences in the temporal and spatial distribution of FDG uptake between lesions of HL and DLBCL. OUTLINE: Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans 60 and 180 minutes after FDG administration. After completion of study, patients are followed for 24 hours.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Abramson Cancer Center of the University of Pennsylvania.